The Bigger Point Beyond Insilico's Aging Research Milestone

The news received widespread media attention, including mainstream outlets such as The NYT, WSJ, and Bloomberg, but almost all titles focus on the potential ability of rentosertib to slow aging, while I think the story has a bigger point that could be more impactful for the area of aging research and the longevity industry. 

The drug itself may well turn out to be a geroprotector, and the paper is honest that its own data leaves that question open (for now). What the study does settle is that aging can be measured as an exploratory endpoint inside a normal, regulated, placebo-controlled trial run for a conventional disease indication. That is a template for others to follow, and templates travel further than single results.

But before we jump into that, let's review the actual results beyond the hype, and some caveats.

What was actually measured 

Rentosertib is a TNIK inhibitor developed for idiopathic pulmonary fibrosis. Its phase 2a clinical trial ran across sites in China through 2023 and 2024, and it was reported in Nature Medicine in June 2025 that it met its primary safety endpoint with a dose-dependent efficacy trend, including a mean forced vital capacity improvement of 98.4 mL in the 60 mg once-daily arm against a 20.3 mL decline on placebo. The drug has since advanced to phase III clinical trial.

The phase 2a trial protocol had prospectively included longitudinal serum proteomic collection as an exploratory biomarker layer.